<DOC>
	<DOCNO>NCT00545480</DOCNO>
	<brief_summary>This 2 arm study assess impact bone marker feedback , use blood sample communication result week 5 , persistence monthly Bonviva ( 150mg po ) woman post-menopausal osteoporosis . The study also assess safety , quality life patient satisfaction . All patient receive Bonviva 150mg po monthly , randomize bio-feedback bio-feedback study arm . The anticipated time study treatment 3-12 month , target sample size 500+ individual .</brief_summary>
	<brief_title>SUMMIT Study : A Study Persistence Bonviva ( Ibandronate ) Once Monthly Women With Post-Menopausal Osteoporosis .</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>ambulatory , postmenopausal woman would benefit bisphosphonate treatment ; &gt; 55 year age ; naive bisphosphonate therapy , lapse bisphosphonate user &gt; =6 month . inability stand sit upright position least 60 minute ; hypersensitivity bisphosphonates ; treatment drug affect bone metabolism ; history major upper gastrointestinal disease .</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>